Why Hims & Hers (HIMS) rose 11.57%
Hims & Hers (HIMS) rose 11.57% on August 20, 2026 — Moderna cancer vaccine breakthrough lifts biopharma.
What happened
Moderna disclosed a cancer-vaccine breakthrough, triggering a broad biopharma rally that lifted the Healthcare & Biotech theme.
Why it moved
Hims rose in sympathy with sector peers as Moderna's vaccine success reignited conviction in the biotech pipeline; the broader basket moved higher on restored optimism around novel therapeutics, lifting Hims alongside…
Why it matters
The Healthcare & Biotech theme has stalled waiting for fresh clinical validation after a three-month obesity-drug and vaccine surge; Moderna's cancer-vaccine win signals that pipeline momentum is alive, re-engaging…
What would break the thesis
If Moderna's vaccine data falters in later trials or obesity-drug adoption slows below expectations, the sector-wide momentum reverses and Hims loses its tailwind.